Kellam P - Search Results

1

Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates.

Boucher CA, van Leeuwen R, Kellam P, Schipper P, Tijnagel J, Lange JM, Larder BA. Boucher CA, et al. Among authors: kellam p. Antimicrob Agents Chemother. 1993 Jul;37(7):1525-30. doi: 10.1128/AAC.37.7.1525. Antimicrob Agents Chemother. 1993. PMID: 8103317 Free PMC article.

2

HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment.

Boucher CA, Lange JM, Miedema FF, Weverling GJ, Koot M, Mulder JW, Goudsmit J, Kellam P, Larder BA, Tersmette M. Boucher CA, et al. Among authors: kellam p. AIDS. 1992 Nov;6(11):1259-64. doi: 10.1097/00002030-199211000-00003. AIDS. 1992. PMID: 1282015

3

Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects.

Boucher CA, O'Sullivan E, Mulder JW, Ramautarsing C, Kellam P, Darby G, Lange JM, Goudsmit J, Larder BA. Boucher CA, et al. Among authors: kellam p. J Infect Dis. 1992 Jan;165(1):105-10. doi: 10.1093/infdis/165.1.105. J Infect Dis. 1992. PMID: 1370174

4

Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy.

Boucher CA, Tersmette M, Lange JM, Kellam P, de Goede RE, Mulder JW, Darby G, Goudsmit J, Larder BA. Boucher CA, et al. Among authors: kellam p. Lancet. 1990 Sep 8;336(8715):585-90. doi: 10.1016/0140-6736(90)93391-2. Lancet. 1990. PMID: 1975378

5

Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates.

Kellam P, Larder BA. Kellam P, et al. Antimicrob Agents Chemother. 1994 Jan;38(1):23-30. doi: 10.1128/AAC.38.1.23. Antimicrob Agents Chemother. 1994. PMID: 8141575 Free PMC article.

6

Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine.

Kellam P, Boucher CA, Larder BA. Kellam P, et al. Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1934-8. doi: 10.1073/pnas.89.5.1934. Proc Natl Acad Sci U S A. 1992. PMID: 1371886 Free PMC article.

7

Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes.

Larder BA, Kellam P, Kemp SD. Larder BA, et al. Among authors: kellam p. AIDS. 1991 Feb;5(2):137-44. doi: 10.1097/00002030-199102000-00002. AIDS. 1991. PMID: 1709563

8

Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.

St Clair MH, Martin JL, Tudor-Williams G, Bach MC, Vavro CL, King DM, Kellam P, Kemp SD, Larder BA. St Clair MH, et al. Among authors: kellam p. Science. 1991 Sep 27;253(5027):1557-9. doi: 10.1126/science.1716788. Science. 1991. PMID: 1716788

9

Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance.

Kellam P, Boucher CA, Tijnagel JM, Larder BA. Kellam P, et al. J Gen Virol. 1994 Feb;75 ( Pt 2):341-51. doi: 10.1099/0022-1317-75-2-341. J Gen Virol. 1994. PMID: 7509370

10

Retroviral recombination can lead to linkage of reverse transcriptase mutations that confer increased zidovudine resistance.

Kellam P, Larder BA. Kellam P, et al. J Virol. 1995 Feb;69(2):669-74. doi: 10.1128/JVI.69.2.669-674.1995. J Virol. 1995. PMID: 7529334 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

318 results

Search Page

Filters